{"name":"Tammie L. S. Benzinger, MD, PhD","slug":"tammie-l-s-benzinger-md-phd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"F 18 T807","genericName":"F 18 T807","slug":"f-18-t807","indication":"Other","status":"phase_2"},{"name":"Drug: F 18 T807","genericName":"Drug: F 18 T807","slug":"drug-f-18-t807","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"F 18 T807","genericName":"F 18 T807","slug":"f-18-t807","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Drug: F 18 T807","genericName":"Drug: F 18 T807","slug":"drug-f-18-t807","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQN2kzRXFuLUZjQnBsOGwtamZyUzBSeUFJNFhiUjlDakctU29NU1lJNE1FcnhlQmF2X2tCelJuWlBZNndUZF9fX1IyZ1h2bUNSWnZZMzk4bzNNMnNJcXd1RTNyQ05wM3R1V0dpZ1NBLTR5bGtzRWp4V1Z0YnFCdU01UjBselpKbkNOSGxBYnpxQXY?oc=5","date":"2025-01-07","type":"pipeline","source":"jnm.snmjournals.org","summary":"Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup - jnm.snmjournals.org","headline":"Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nucl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBFdHlfVVkzdVNmS3NNVDYxQ0J6REZ5U0x6SzV1bHZxQmg1MS1vaERyS05tS2hzakt5X0IyRERGekstaFZzakg4N0YwdU91MXBfMWJacFh4eTBuSlJMVjlyX2dnUmhaLXpDRDdRbjgtQkxBVVd1bmNidExhVFo?oc=5","date":"2024-02-23","type":"trial","source":"Wiley","summary":"Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease - Wiley","headline":"Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE90MnM0Rk0zUjZGNGZYR2pEZlhFSHdTR2JmZTZhZk1IZlJucG9vRHhhR2hPTk96ei1hUkJfa255MGJ1Smx4NUg3MGNzNHJTNWxoNDctVFhDNlNsdVl6ZjhBS2w1Y3VVcjhSTE04Sg?oc=5","date":"2011-09-22","type":"pipeline","source":"ahajournals.org","summary":"Postcontrast Susceptibility-Weighted Imaging: - ahajournals.org","headline":"Postcontrast Susceptibility-Weighted Imaging:","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}